# Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)

> **NCT04141631** · NA · COMPLETED · sponsor: **University Hospital, Montpellier** · enrollment: 128 (actual)

## Conditions studied

- Cardiac Surgery
- Transfusion
- Perioperative Anemia

## Interventions

- **DRUG:** EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)

## Key facts

- **NCT ID:** NCT04141631
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-13
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-06-15
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141631, "Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04141631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*